Zale Corp. (ZLC) Tops Q2 EPS by 1c, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts ZLC Hot Sheet
Price: $21.02 --0%
Financial Fact:
Operating earnings: 13.92M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Operating earnings: 13.92M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Zale Corp. (NYSE: ZLC) reported Q2 EPS of $0.78, $0.01 better than the analyst estimate of $0.77. Revenue for the quarter came in at $663.8 million versus the consensus estimate of $657.38 million.
For earnings history and earnings-related data on Zale Corp. (ZLC) click here.
For earnings history and earnings-related data on Zale Corp. (ZLC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- Ascendis Pharma (ASND) Tops Q2 EPS by 132c
- Legence Corp. (LGN) Misses Q2 EPS by 58c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
